Dimopoulos MA et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial. J Clin Oncol 2023;41(8):1590-9. Abstract
Dimopoulos MA et al. Daratumumab plus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(6):801-12. Abstract
Facon T et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA. Leukemia 2022;36(4):1066-77. Abstract
Facon T et al. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: Ikema subgroup analysis. ASH 2022;Abstract 4553.
Goldschmidt H et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9:e810-21. Abstract
Kumar SK et al. Fixed duration daratumumab, ixazomib, lenalidomide, and dexamethasone quadruplet for newly diagnosed multiple myeloma - MRD negativity and survival outcomes. ASH 2022;Abstract 4559.
Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized phase 3 study. Blood Cancer J 2023;13(1):72. Abstract
Mateos M-V et al. Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 Ithaca study. ASH 2022;Abstract 4561.
Moreau P et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Clinical assessment of key subgroups of the phase 3 maia study. ASH 2022;Abstract 3245.
Quach H et al. Subcutaneous (sc) isatuximab administration by an on-body delivery system (OBDS) in combination with pomalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: Phase 1b expansion study results. ASCO 2022;Abstract 8025.
Richardson PG et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study. Lancet Oncol 2022;23(3):416-27. Abstract
Sborov D et al. Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): Final analysis of GRIFFIN. IMS 2022;Abstract OAB-057.
Usmani SZ et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol 2022;23(1):65-76. Abstract
Usmani SZ et al. Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. Haematologica 2022;107(10):2408-17. Abstract
Weisel KC et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (isa-KRd) in patients with high-risk, newly diagnosed multiple myeloma: Planned interim analysis of the GMMG-CONCEPT trial. ASH 2022;Abstract 759.